Home › Compound Library › Thymosin Alpha-1
Immune modulation
Thymosin Alpha-1: The Immune Peptide With a Thirty-Year Clinical Record
The short answer
Thymosin alpha-1 is a 28-amino-acid peptide first isolated from the thymus, the gland that trains the immune system. It is an approved medicine in more than thirty countries and has been studied in hepatitis, sepsis and cancer care for three decades. In the US it is not approved, though it holds FDA orphan drug designation for four conditions.
Questions people ask about Thymosin Alpha-1
- What is thymosin alpha-1?
- Is thymosin alpha-1 FDA approved?
- What is thymosin alpha-1 used for?
- Is thymosin alpha-1 the same as thymosin beta-4?
- Does thymosin alpha-1 help the immune system?
- What are thymosin alpha-1’s side effects?
- Is thymosin alpha-1 banned in sport?
- Thymosin alpha-1 vs KPV: which one?
Thymosin Alpha-1 at a glance
| Also called | Tα1; thymalfasin; Zadaxin (brand name) |
|---|---|
| What it is | A 28-amino-acid peptide, the active fragment of prothymosin alpha from the thymus |
| Acts on | Toll-like receptors on dendritic cells; T-cell maturation and function |
| Main system | Immune regulation: infection, inflammation, cancer care |
| Evidence level | Randomised controlled trials and meta-analyses, including a multicentre sepsis trial |
| FDA status (Sept 2026) | Not approved in the US. Holds orphan drug designation for four conditions and is approved in more than thirty countries |
| In sport | Not named on the 2026 WADA prohibited list |
What is thymosin alpha-1?
The thymus is where T cells learn to tell friend from foe. It is also the organ that shrinks earliest and fastest with age, which is part of why immune function declines. Thymosin alpha-1 is a peptide isolated from thymus tissue in the 1970s and identified as one of the signals behind that training role.
It is a genuine hormone fragment rather than a designer molecule: 28 amino acids cut from a larger protein the body makes, now produced synthetically.
Regenerative Resilience profiles it at pp. 124–126, The Cognitive Advantage at pp. 185–191, Targeted Peptide Systems at pp. 206–208, and The Longevity Map at p. 91.
How does thymosin alpha-1 work?
It works upstream of the inflammation itself, on how the immune system is directed:
- Dendritic cells. It signals through Toll-like receptors on dendritic cells, the cells that decide what the immune system reacts to and how strongly.
- T-cell maturation. It supports the development and function of T cells, the arm of immunity that handles viruses and abnormal cells.
- Restoring balance rather than suppressing. The pattern across the research is a system brought back towards normal regulation: it can lift a suppressed response and damp an overactive one.
Regenerative Resilience (p. 125) frames this as the difference that matters in protocol terms: a compound that restores immune regulation is doing something categorically different from one that suppresses immune function, and the two should not be swapped for each other.
What does the research show?
The strongest recent evidence is in sepsis. The TESTS trial, published in the BMJ in 2025, was a multicentre, double-blinded, randomised trial of thymosin alpha-1 in adults with sepsis (reference 1). A 2025 systematic review and meta-analysis of randomised trials in sepsis reached broadly supportive conclusions (reference 2). This is a higher evidence tier than most compounds in this library reach.
Infectious disease is where its clinical history sits. A 2015 historical review in Expert Opinion on Biological Therapy traces three decades of use in chronic hepatitis B and C and as an adjuvant, which is the basis for its approvals abroad (reference 3).
Immune regulation as a mechanism is covered in a 2007 review in the Annals of the New York Academy of Sciences describing it as an endogenous regulator of inflammation, immunity and tolerance (reference 4), the paper Targeted Peptide Systems draws on.
Where the evidence stands. Most of the trial work sits in acute clinical settings: sepsis, hepatitis, cancer adjuvant care, critical illness. The uses it is discussed for outside those settings, such as general immune support or post-viral recovery, are extrapolations from that work rather than conclusions of it.
Side effects and cautions
The safety record is the unusual strength here. Three decades of clinical use across more than thirty countries, in populations that were often seriously ill, without a signal of significant toxicity. Injection-site reactions are the most commonly reported effect.
The theoretical caution is the flip side of the mechanism: a compound that restores immune activity deserves care in autoimmune disease, where the immune system is already directed at the wrong target, and alongside immunosuppressive therapy after transplant. Those are conversations for the clinician managing that condition, not questions to settle alone.
In the US the practical risk is sourcing. Material sold outside a prescription route has no manufacturer answerable for what is in the vial, which is what third-party testing exists to cover.
Is thymosin alpha-1 legal or FDA approved?
Not approved in the US. Thymosin alpha-1 has never been approved by the FDA for any indication. It is approved in more than thirty countries, generally for chronic hepatitis B and C and as a cancer adjuvant.
It does hold FDA orphan drug designation for four conditions: malignant melanoma, chronic active hepatitis B, DiGeorge anomaly and hepatocellular carcinoma. Designation is a development incentive, giving a sponsor fee relief and market exclusivity if the drug is later approved. Press releases often describe it as the FDA approving orphan drug status, which reads like approval and is not the same thing.
It was not among the six peptides the FDA advisory committee recommended for compounding in July 2026 (references 5, 6).
Sport: thymosin alpha-1 is not named on the 2026 WADA prohibited list, unlike thymosin beta-4, which is prohibited. Athletes should check with their governing body.
Thymosin alpha-1 vs thymosin beta-4, KPV and the other immune compounds
The names cause more confusion here than the biology does.
- vs thymosin beta-4 and TB-500: despite the shared name, these are unrelated molecules with different jobs. Thymosin beta-4 works on actin and tissue repair. Thymosin alpha-1 works on immune regulation. One is a repair compound, the other an immune compound.
- vs KPV: KPV damps a single inflammatory signalling pathway. Thymosin alpha-1 works further upstream on how the immune response is directed. KPV is the narrower tool with the earlier evidence base; thymosin alpha-1 is the broader one with the clinical record.
- vs corticosteroids: steroids suppress immune function broadly. Thymosin alpha-1 aims to restore regulation, which is a different intention rather than a weaker version of the same one.
Our article on the immune rules most protocols ignore covers how the books decide between them.
Risk, benefit, and the conversation this page is for
How to weigh it. This is the compound in the library where the evidence argument runs the other way. Thymosin alpha-1 has randomised controlled trials, meta-analyses and thirty years of clinical use across more than thirty countries behind it, much of it in seriously ill patients, without a significant toxicity signal emerging. The gap here is regulatory rather than scientific: no sponsor has taken it through the US approval process.
The regulatory picture, read carefully. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. Thymosin alpha-1 was not among them, and it has never been approved in the US. What it does hold is FDA orphan drug designation for four conditions, which is recognition that the science is taken seriously rather than clearance to sell it here. Reading those decisions one at a time is more useful than treating every compound outside the approved list as equivalent.
Where the real caution sits. Not toxicity, but direction. A compound that restores immune activity deserves care in autoimmune disease and alongside immunosuppressive therapy after a transplant, because in both cases the immune system is already being managed on purpose. That is a conversation with the clinician managing that condition, and it is the kind of question the due diligence exists for: what your baseline looks like, what else you are taking, what you would measure, and what would tell you to stop.
Which is the point of the series. Nothing here is a recommendation to use thymosin alpha-1. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Thymosin Alpha-1: frequently asked questions
What is thymosin alpha-1?
A 28-amino-acid peptide from the thymus that helps direct immune responses, largely through dendritic cells and T-cell function. It is approved as a medicine in more than thirty countries.
Is thymosin alpha-1 FDA approved?
No. It has never been approved in the US for any indication. It holds FDA orphan drug designation for four conditions, which is a development incentive rather than clearance to sell it here.
What is thymosin alpha-1 used for?
Abroad, chronic hepatitis B and C and as a cancer adjuvant. In trials it has been studied in sepsis and critical illness (references 1, 2).
Is thymosin alpha-1 the same as thymosin beta-4?
No. They share a name and an organ of origin and nothing else. Thymosin beta-4 works on actin and tissue repair; thymosin alpha-1 works on immune regulation.
Does thymosin alpha-1 help the immune system?
The research describes it as restoring regulation rather than simply boosting activity, which is why it has been studied both where immunity is suppressed and where it is overactive.
What are thymosin alpha-1’s side effects?
The record across three decades of clinical use is unusually quiet, with injection-site reactions the most commonly reported. The theoretical caution is autoimmune disease, where restoring immune activity deserves care.
Is thymosin alpha-1 banned in sport?
It is not named on the 2026 WADA prohibited list, though thymosin beta-4 is. Check with your sport’s governing body, as lists change each year.
Thymosin alpha-1 vs KPV: which one?
They work at different levels. KPV damps one inflammatory pathway; thymosin alpha-1 works upstream on how the immune response is directed, and has the far larger clinical record.
Where Thymosin Alpha-1 appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Thymosin Alpha-1 fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Thymosin Alpha-1 fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised controlled trial. BMJ. 2025;388:e082583. View source
- Gu B, Zhou Y, Nie Y, et al. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2025;15:1673959. View source
- Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117–S127. View source
- Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326–338. View sourceRelated to the Goldstein review cited in Targeted Peptide Systems
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Thymosin Alpha-1 is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.